top of page
Ajaya Bio is a preclinical-stage biotech company developing BOLT-360™, a bispecific antibody platform with the power to reshape the treatment landscape for autoimmune diseases and oncology. With unmatched specificity, safety, and access to previously untargetable pathways, Ajaya Bio is unlocking new frontiers in patient care.

Lead Program & Pipeline

  • Lead target: CD23

  • Indications: Myasthenia Gravis (MG), Chronic Lymphocytic Leukemia (CLL)

  • Market: ~$2B (U.S.)

  • Expanding to CD40-CD40L (SLE) and Fas (GBM), with 8 advanced candidates in development

Technology Differentiators

  • Minimizes off-target effects without depleting healthy immune cells

  • Overcomes toxicity and resistance in Fas pathway targeting

  • Proven versatility: 50+ proteins screened, 20 hits, 8 preclinical leads

Stage & Investment

  • Stage: Preclinical

  • Funding Raised: <$500K (Friends & Family)

  • Seeking: Seed funding (~$6M) for candidate validation, CMC development, and pipeline expansion

  • IP: Two patents filed, third in progress

What's Next

  • Deliver lead candidate with compelling preclinical data

  • Advance toward IND-enabling studies

  • Build pharma partnerships and investor momentum

Leadership

Mohit-Ajaya.jpg
Mohit Sachdeva, PhD, MBA
Founder & CEO
Ramesh-Singh.jpg
Ramesh Singh, PhD
Scientific Lead
bottom of page